NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Hold” from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned an average rating of “Hold” from the fifteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.00.

A number of research firms have commented on NEO. Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Friday, September 12th. TD Cowen raised their price target on NeoGenomics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday. Needham & Company LLC increased their target price on NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Finally, Leerink Partners set a $14.00 target price on NeoGenomics in a report on Tuesday, October 28th.

Insiders Place Their Bets

In related news, EVP Alicia C. Olivo sold 20,916 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total transaction of $250,992.00. Following the completion of the transaction, the executive vice president owned 31,083 shares in the company, valued at approximately $372,996. The trade was a 40.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. bought a new stake in shares of NeoGenomics in the 3rd quarter valued at $106,000. CANADA LIFE ASSURANCE Co grew its stake in NeoGenomics by 11.4% in the third quarter. CANADA LIFE ASSURANCE Co now owns 150,140 shares of the medical research company’s stock valued at $1,166,000 after acquiring an additional 15,403 shares during the period. Dark Forest Capital Management LP bought a new stake in shares of NeoGenomics in the third quarter worth about $977,000. Voloridge Investment Management LLC raised its position in shares of NeoGenomics by 17.2% during the third quarter. Voloridge Investment Management LLC now owns 1,234,870 shares of the medical research company’s stock worth $9,533,000 after purchasing an additional 181,072 shares during the period. Finally, Verition Fund Management LLC raised its position in shares of NeoGenomics by 17.3% during the third quarter. Verition Fund Management LLC now owns 257,012 shares of the medical research company’s stock worth $1,984,000 after purchasing an additional 37,873 shares during the period. 98.50% of the stock is owned by institutional investors.

NeoGenomics Stock Performance

Shares of NASDAQ:NEO opened at $11.67 on Wednesday. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $19.11. The stock has a market capitalization of $1.51 billion, a P/E ratio of -13.26 and a beta of 1.60. The business has a 50-day moving average price of $10.74 and a two-hundred day moving average price of $8.44.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.02 by $0.01. The company had revenue of $187.80 million during the quarter, compared to analysts’ expectations of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. NeoGenomics’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Equities analysts predict that NeoGenomics will post -0.2 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.